The roles of mitoferrin-2 in the process of arsenic trioxide-induced cell damage in human gliomas by Chunlei Wang et al.
EUROPEAN JOURNAL 
OF MEDICAL RESEARCH
Wang et al. European Journal of Medical Research 2014, 19:49
http://www.eurjmedres.com/content/19/1/49RESEARCH Open AccessThe roles of mitoferrin-2 in the process of arsenic
trioxide-induced cell damage in human gliomas
Chunlei Wang†, Xiaofeng Chen†, Huichao Zou, Xin Chen, Yaohua Liu and Shiguang Zhao*Abstract
Background: Among glioma treatment strategies, arsenic trioxide (As2O3) has shown efficacy as a therapeutic agent
against human gliomas. However, the exact antitumor mechanism of action of As2O3 is still unclear. Mitochondria are
considered to be the major source of intracellular reactive oxygen species (ROS), which are known to be associated
with As2O3-induced cell damage. Therefore, we investigated whether mitoferrin-2, a mitochondrial iron uptake
transporter, participates in As2O3-induced cell killing in human gliomas.
Methods: Human glioma cell lines were used to explore the mechanism of As2O3’s antitumor effects. First,
expression of mitoferrin-2 was analyzed in glioma cells that were pretreated with As2O3. Changes in ROS production and
apoptosis were assessed. Furthermore, cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT).
Results: In the present study we found that As2O3 induced ROS production and apoptosis in glioma cells. In addition,
gene expression of mitoferrin-2, a mitochondrial iron uptake transporter, was increased 4 to 5 fold after exposure to
As2O3 (5 μM) for 48 hours. Furthermore, apoptosis and cytotoxicity induced by As2O3 in glioma cells were decreased after
silencing the mitoferrin-2 gene.
Conclusions: Our findings indicated that mitoferrin-2 participates in mitochondrial ROS-dependent mechanisms
underlying As2O3-mediated damage in glioma cells.
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Glioma is a serious life-threatening disease, having the
characteristics of invasiveness and a dismal prognosis.
Chemotherapy and/or radiotherapy are the main ap-
proaches for glioma treatment after surgery. As2O3 as an
antitumor agent has shown efficacy in treating glioma in
laboratory tests [1,2]. Additionally, As2O3 has potential
as a mitochondrial toxin that can induce reactive oxygen
species (ROS) production; these mainly originate in the
intracellular mitochondrial respiratory chain and further
toxic byproducts subsequently produced could lead to
mitochondrial damage [3]. In addition, excessive ROS pro-
duction acts as key mediator of the apoptotic-signaling
pathway. However, the detailed mechanism of As2O3-in-
duced excessive ROS production remains unclear.* Correspondence: guangsz@hotmail.com
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unless otherwise stated.Among numerous possible factors, such as altering the
activity of enzymes, kinases, phosphatases and transcrip-
tion factors [4], iron has been demonstrated in previous
studies [5-9] to play an important role during ROS pro-
duction in the mitochondrion. Because of the character
of its redox properties, iron can catalyze the production
of ROS, which are highly toxic [10], and increase the
redox reaction [11].
Two main forms of iron exist in the cell: non-chelatable
iron and chelatable iron. Lysosomes store amounts of
chelatable iron [12], which promotes oxidative stress by
catalyzing the Fenton reaction and produces highly react-
ive hydroxyl radicals. Excessive reactive hydroxyl radicals
could damage DNA, proteins, and membranes. The con-
centration of cytosolic chelatable iron is low under normal
conditions, but, in pathological conditions, chelatable iron
released from lysosomes can increase cytosolic iron con-
centration [12]. Additionally, thelysosome-damaging abil-
ity of arsenite has been demonstrated [13] and it is alsoThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Wang et al. European Journal of Medical Research 2014, 19:49 Page 2 of 10
http://www.eurjmedres.com/content/19/1/49known that excessive mitochondrial ROS production re-
quires more iron to cross the mitochondrial membrane.
Therefore, we hypothesized that the mitochondrial iron
transporter may participate in As2O3-induced excessive
ROS production.
Mitochondria are considered to be the major source of
intracellular ROS, which are knowingly associated with
retrograde signaling and affect many cellular functions
[14-16]. Mitoferrin, a mitochondrial protein, has been
reported to mediate ferrous iron transport across the
mitochondrial inner membrane [11,17,18]. Mitoferrin
has two isoforms: mitoferrin-1 and mitoferrin-2, which
are localized on the inner mitochondrial membrane and
function as a requisite importer of iron for mitochon-
drial heme and iron-sulfur cluster (ISC) in erythroblasts
[11]. Mitoferrin-1 is mainly distributed in erythroid cells
with low levels in other tissues, whereas mitoferrin-2 is
ubiquitously distributed [19]. In non-erythroid cells,
mitoferrin-2 possibly functions to maintain the levels of
cellular mitochondrial iron [11,19]. Previous research has
reported that mitoferrin-2 transmits ferrous iron from
cytoplasm to mitochondria. Additionally high mitoferrin-
2-expressing cells showed higher rates of mitochondrial
ferrous iron uptake compared with low mitoferrin-2-
expressing cells [20]. Therefore, the possibility that the
mitoferrin-2 transporter participates in As2O3-induced
apoptosis in glioma should be considered.
In this study, our aim is to investigate whether
mitoferrin-2 participates in the cytotoxic effect of As2O3
in human glioma and mediates the production of ROS.
Methods
Source of reagents
As2O3 compound was obtained from the Department of
Pharmacy, the First Affiliated Hospital of Harbin Med-
ical University (Harbin, China), and fresh dilutions with
DMEM were used in each experiment. Mitoferrin-2
siRNA was designed and purchased from GenePharma
(Shanghai, China). Annexin V-FITC-PI apoptosis de-
tection kit (Baosea Biotechnology Co., Beijing, China)
was used for detection of apoptosis by flow cytometry.
For detection of ROS activity, 2′,7′-dichlorofluorescin
diacetate (Sigma-Aldrich, St. Louis, MO, USA) was
used. Reverse transcriptase RT kit and real time PCR
kit (Takara Biotechnology Co., Shiga, Japan) were used
for the semiquantitation of mitoferrin-2 mRNA
levels. Dimethylsulfoxide (DMSO) and 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Sigma-Aldrich, St. Louis, MO, USA) were used for
detection of cell viability.
Cell culture
Human glioma cell lines, U87MG and T98G were cul-
tured in DMEM(Hyclone, Logan, UT, USA) supplementedwith 10% FBS(Hyclone, Logan, UT, USA) at 37°C in a hu-
midified CO2 incubator, and 1% penicillin-streptomycin.
The cells were passaged twice weekly, and once they were
nearly confluent, they were released with 0.25% trypsin-
ethylenediaminetetraacetic acid (EDTA) [21].
RNA interference studies
The siRNA specific sequences of human mitoferrin-2 trans-
porter were designed according to standard procedures,
and obtained from Shanghai GenePharma (Shanghai,
China). The sequences were:
5′-GGCAACAUUACUUCAUGAUTT-3′ and 5′-AUC
AUGAAGUAAUGUUGCCTT-3′; and the negative con-
trol sequences were:
5′-UUCUCCGAACGUGUCACGUTT-3′ and 5′-ACG
UGACACGUUCGGAGAATT-3′. Glioma cells were
transfected with 40 pmol of siRNA duplex or negative
groups and exposed to 5 μM As2O3 for 48 hours.
Quantitative realtimePCR (QRT-PCR)
Total RNA was isolated from glioma cells using Trizol re-
agent (Invitrogen, California, USA). It was then reverse-
transcribed to cDNA with random primers using a reverse
transcriptase RT kit (Takara Biotechnology Co., Shiga,
Japan) [22]. The mRNA levels of mitoferrin-2 expression
were detected using QRT-PCR on a Light Cycler 480
(Roche Diagnostics, Basel, Switzerland) according to the
manufacturer’s protocol. The primer set of mitoferrin-2
was: sense, 5′-GGAGCATTCCAGGAGACA-3′; antisense,
5′-GGGTGACCGCCTATTT-3′. Each sample was checked
in triplicate, and parallel reactions were performed using
primers to β-actin as an internal control. The data were an-
alyzed using the Light Cycler 480 software.
Western blot analysis
Cell extracts were prepared in ice-cold radioimmune
precipitation assay lysis buffer (150 mM NaCl, 1 mM
ethylene glycol tetraacetic acid (EGTA), 1% sodium
deoxycholate, 1% Triton X-100, 0.1% SDS, 1% Nonidet
P-40, 50 mM Tris-Cl, pH 7.4) supplemented with a mix-
ture of protease inhibitors (Roche Diagnostics, Basel,
Switzerland) and centrifuged. Equivalent amounts of pro-
tein determined by Bradford assay (Bio-Rad, California,
USA) in sample buffer (Invitrogen) supplemented with
10% SDS and 10% β-mercaptoethanol were resolved on
NuPAGE Tris-bis 12% polyacrylamide gels (Invitrogen,
California, USA). Proteins were transferred to polyvinyli-
dene difluoride (PVDF) membranes (EMD Millipore, arm-
stadt, Germany) and probed with anti-Mfrn-2 (1:100)
(Santa Cruz Biotechnology, Shanghai, China) and anti-β-
actin (1:1,000) (Santa Cruz Biotechnology). Membranes
were developed by two-color infrared fluorescence im-
aging system (LI-COR Biosciences, Nebraska, USA).
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Glioma cells were transfected with 40 pmol of siRNA
duplex or negative groups and exposed to 5 μM As2O3
for 48 hours. Then cells were incubated with 10 μM
2′,7′-dichlorofluorescin diacetate (Sigma-Aldrich, St.
Louis, MO, USA) for 30 minutes, after which they were
washed. ROS generation was determined by FACS can
flow cytometry (Becton-Dickinson Mountain View, CA,
USA) using CellQuest software and fluorescent signals
were displayed as histograms.
MTT analysis
To investigate cell viability, U87MG and T98G cells
were seeded in 96-well plates at a density of 5 × 103 cells
per well and stabilized for 24 hours. Glioma cells were
transfected with 40 pmol of siRNA duplex or negative
groups and exposed to 5 μM As2O3 for 48 hours. The
cells were incubated with new culture medium contain-
ing MTT working solution (0.5mg/ml) for 4 hours at
37°C. The culture supernatant was removed from the
wells, and dimethyl sulfoxide (DMSO) was added. The
absorbance of each well was measured at a wavelength
of 490 nm with a reader.
Apoptosis
The apoptosis-inducing effects of As2O3 in U87MG and
T98G cells were determined by flow cytometery using
Annexin-V/FITC and propidium iodide. About 0.5 × 106
cells were plated in each well of a 6-well plate and trans-
fected with 40 pmol of siRNA duplex or negative groups
and exposed to 5 μM As2O3 for 48 hours. Apoptosis
was determined using human Annexin-V-FITC kit ac-
cording to the manufacturer’s instructions and analyzed
by flow cytometry. Tests were repeated in triplicate.
Statistical analysis
Statistical analysis was performed by Student’s t-test.
P-values of <0.05 were considered statistically significant.Figure 1 After exposure of human glioma cell lines U87MG (A) and T
of As2O3 was analyzed by MTT. Student’s t-test was used for evaluation
2,5-diphenyltetrazolium bromide.All values are expressed as mean ± SEM from three dif-
ferent experiments.
Results
Effects of As2O3 on cell viability in glioma
The sensitivity of U87MG and T98 G cells to As2O3
was first investigated by MTT. Figure 1 shows that the
cytotoxic effect of a 48-hour treatment with As2O3 was
dose-dependent, and 5 μM was chosen as the optimal
concentration for As2O3 treatment in U87MG (Figure 1A)
and T98G (Figure 1B).
Induction of ROS and oxidative stress by As2O3
To explore the effect of As2O3 on oxidative stress pro-
duction in glioma cells, the ROS production induced by
As2O3 in U87MG and T98G was measured. At 2 hours,
4 hours, 6 hours or 8 hours after exposure to 5 μM
As2O3, the intracellular ROS levels were increased and
the peak production appeared at 6 hours and 4 hours re-
spectively in U87MG (Figure 2A) and T98G cell lines
(Figure 2B). Therefore, 6 hours and 4 hours were chosen
times to monitor ROS production for the follow-up tests
in U87MG and T98G, respectively.
As2O3 enhanced the expression of mitoferrin-2 in glioma
cells
To explore the possible mechanism of As2O3-induced
cell damage and ROS production, we measured the cel-
lular mitoferrin-2 expression after pretreatment with
As2O3 (5 μM) for 48 hours. Our data from QRT-PCR
showed that the expression of mitoferrin-2 was in-
creased about 4 to 5 folds in both U87MG (Figure 3A)
and T98G lines (Figure 3B) after As2O3 pretreatment.
The mitoferrin-2 expression after silencing was also
measured by QRT-PCR. As shown in Figure 3, the ex-
pression rate of mitoferrin-2 mRNA decreased about
67.4% and 43.4% respectively in U87MG (Figure 4A)
and T98G lines (Figure 4B) transfected with mitoferrin-298G (B) to As2O3 at different doses for 48 hours, the cytotoxicity
statistical significance (*P < 0.05).MTT, 3-(4,5-dimethylthiazol-2-yl)-
Figure 2 After exposure of human glioma cell lines U87MG (A) and T98G (B) to As2O3 at different times, the reactive oxygen species
(ROS) production of As2O3 was analyzed by flow cytometry. Student’s t-test was used for evaluation statistical significance (*P < 0.05).
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cleotides. Mitoferrin-2 expression measured by Western
blot analysis (Figure 5) produced the same results as
with QRT-PCR.
ROS production and apoptosis in As2O3-treated glioma
cells decreased after silencing the mitoferrin-2 expression
To confirm the role of mitoferrin-2 transporter in As2O3
treatment of glioma cells, we modulated mitoferrin-2expression in U87MG and T98G by using siRNA inter-
ferencing. For those cells pretreated with As2O3 (5 μM),
the ROS production (Figure 6), apoptosis (Figure 7) and
cell death rates (Figure 8) were decreased after silencing
the mitoferrin-2 transporter. siRNA-mediated inhibition
of As2O3-induced apoptosis is greater in T98MG com-
pared with U78MG (Figure 7). These data indicated
mitoferrin-2 silencing strongly protected against ROS
production induced by As2O3.
Figure 3 Treatment with As2O3 (5 μM, 4 8hours) significantly increased intracellular mitoferrin-2 expression in glioma cells U87MG
(A) and T98G lines (B). Data are presented as mean ± SEM for the separate experiments performed in duplicate. Student’s t-test was used to
evaluate statistical significance (*P < 0.05).
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As2O3 has achieved some efficacy in treating glioma
[23-25] although the mechanism remains unclear. In our
study, the results indicated that mitoferrin-2, by mediat-
ing ferrous transport across the mitochondrial inner
membrane, plays a significant role in As2O3-induced gli-
oma cell death. Our findings showed that the expression
level of mitoferrin-2 was increased about 4 to 5 folds in
both U87MG and T98G after pretreatment with As2O3
(5 μM) after 48 hours. Next, to determine whether
mitoferrin-2 mediates mitochondrial ROS production
or apoptosis in As2O3-induced glioma cell damage,
mitoferrin-2 gene expression was silenced by siRNA
in glioma cells and exposed to As2O3 for 48 hours.Figure 4 Silencing mitoferrin-2 by siRNA for 48 hours was shown in U8
after using siRNA interferencing in both U87MG and T98G. Data are presented
Student’s t-test was used to evaluate statistical significance (*P < 0.05).Our data showed that ROS production and apoptosis in
low mitoferrin-2 expression groups were reduced com-
pared to negative control groups in As2O3 pretreated
glioma cells. Additionally, we firstly demonstrated that
down-regulation of mitoferrin-2 expression affects
As2O3-induced cell toxicity in human glioma cell lines
U87MG and T98G. As2O3-induced cytotoxicity was
reduced after silencing mitoferrin-2. Therefore, we as-
sume that mitoferrin-2 transporter may partly partici-
pate in As2O3-induced cytotoxicity through promotion
of ROS production.
Human glioma treatment is especially challenging be-
cause current treatments, such as chemical therapy,
drastically affect patient quality of life. As2O3 has been7MG (A) and T98G (B) lines. Expression of mitoferrin-2 was decreased
as mean ± SEM for the separate experiments performed in duplicate.
Figure 5 The expressions of mitoferrin-2 in cell lysates were detected by Western blotting. β-actin was used as an internal control.
Pretreatment with As2O3 (5 μM, 48 hours) significantly increased intracellular mitoferrin-2 expression in glioma cell lines U87MG and T98G.
Silencing mitoferrin-2 by siRNA for 48 hours was shown in both U87MG and T98G lines.
Figure 6 Reactive oxygen species (ROS) production was measured by flow cytometry in human glioma cell lines U87MG (A) and T98G
(B). The ROS production in the silenced mitoferrin-2 group following pretreatment with As2O3 was decreased compared with the As2O3 (5 μM)
group. Fluorescence signals represent ROS production. Data are presented as mean ± SEM for the separate experiments performed in duplicate.
Student’s t-test was used to evaluate statistical significance (*P < 0.05).
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Figure 7 Apoptosis in As2O3-pretreated human glioma cells was measured by flow cytometry. The apoptosis rate was decreased in the
silenced mitoferrin-2 group (48 hours) following pretreatment with As2O3 (5 μM, 48 hours) compared with the As2O3 (5 μM, 48 hours) group in
both human glioma cell lines U87MG (A) and T98G (B). Student’s t-test was used to evaluate statistical significance (*P < 0.05).
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Figure 8 Proliferation in As2O3-pretreated human glioma cells was measured by MTT. Proliferation rates were not changed in either
human glioma cell lines U87MG (A) or T98G (B) after silencing mitoferrin-2 for 48 hours. Proliferation rates were increased in the silenced mitoferrin-2
group following pretreatment with As2O3 for 48 hours compared with the As2O3 (5 μM) group in both human glioma cell lines U87MG (C) and
T98G lines (D). Student’s t-test was used to evaluate statistical significance (*P < 0.05). MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide.
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als and experiments because of its significant anticancer
property [1,2]. In previous researches, As2O3 (3 to 10
μM) could also induce apoptosis in cultured bone mar-
row mesenchymal stem cells [26,27]. Additionally, treat-
ment with high concentrations of As2O3 (30, 60, and 90
μM) caused primary cardiomyocyte apoptosis in a dose-
and time-dependent manner [28]. Higher concentrations
of As2O3 (4 to 32 μM) obviously reduced smooth muscle
cell viability in a concentration-dependent manner [29].
One clinical study has indicated that the plasma levels of
arsenic are 5.54 to 7.30 μM in acute promyelocytic
leukemia patents treated with As2O3 for detection of
ROS activity [30]. In the present study, we found that
treatment with As2O3 (1 to 10 μM) in glioma cell lines
significantly decreases cell viability and increases cell
apoptosis.
Further, As2O3 is a mitochondrial toxin causing ROS
generation [31], mitochondrial transmembrane potential
disappearance, and cytochrome C release into the
cytoplasm. These phenomena could be the cause of
apoptosis. Therefore, we presume that As2O3 induces
apoptosis in tumor cells possibly by affecting mitochon-
drial function [22,32-38]. Our data showed that highestlevels of As2O3-induced ROS production were after 4
hours and 6 hours in U87MG and T98G cell lines re-
spectively. Additionally, previous researches demon-
strated that intracellular ROS mediates multiple cellular
responses, including cell cycle progression [39], cell dif-
ferentiation [40], and apoptotic cell death [41]. As we
know, ROS is associated with the collapse of matrix
metal proteinases (MMP) and the subsequent oxidative
damage to the mitochondrial membranes, leading to dis-
ruption of MMP, cytochrome release, and apoptosis [42].
Therefore, ROS plays an important role in the antitumor
effect of As2O3.
Previous researches have also reported that iron is as-
sociated with ROS production in some diseases [7]. Be-
cause of its redox properties, the transient existence of
ferrous in mitochondria can catalyze the production of
ROS that can be highly toxic through the Fenton reac-
tion [10]. However, it has long been known that, when
in excess, ROS are among the major determinants of
toxicity in cells and organisms. Therefore, mediated
mitochondrial iron accumulation may affect As2O3-in-
duced ROS production in human glioma.
Mitoferrin-2-dependent mitochondrial iron uptake acts
synergistically to induce photodynamic therapy (PDT)-
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and subsequent cancer cell killing has been reported [20].
Therefore, whether mitoferrin-2 can affect the antitu-
mor effect of As2O3 should be further explored. In our
experiment, mitoferrin-2 mRNA expression was up-
regulated in glioma cells after pretreatment with
As2O3. Thus, mitoferrin-2 may participate in As2O3
treatment. Additionally, previous researches have re-
ported that up-regulated expression of mitoferrin in
yeast and mouse models of Friedreich’s ataxia sug-
gested that it is associated with the pathogenesis of dis-
eases with mitochondrial iron accumulation [43].
Down-regulating the expression of mitoferrin-2 or
blocking the iron import channel by some approaches
should alleviate the symptoms of patients by preventing
iron accumulation [44]. Therefore, we assume that
mitoferrin-2 may regulate mitochondrial iron accumu-
lation and participate in As2O3-induced ROS produc-
tion and cell damage.
In order to further explore whether mitoferrin-2 plays a
crucial role in As2O3-induced cytotoxicity, we measured
ROS production in both down-regulated mitoferrin-2
expression groups and negative groups in glioma cells
pretreated with same-concentration As2O3. Our data
showed that ROS production in low mitoferrin-2 expres-
sion groups was reduced compared to negative groups in
glioma cells pretreated with As2O3. This result suggests
that mitoferrin-2 can regulate As2O3-induced ROS pro-
duction in glioma cells. Additionally, mitoferrin-2 has
been demonstrated to increase the iron transmitted into
mitochondria and to be related to ROS production in
PDT [20]. The predominant proportion of ROS produc-
tion occurs inside mitochondria, leading to mitochondrial
permeability transition and cell death [15]. Therefore,
overall these findings suggest that mitoferrin-2 has
anapoptotic-promotingrole in As2O3-induced glioma
apoptosis and cell damage.
Conclusion
In summary, we have demonstrated for the first time
that mitoferrin-2 transporter plays an important role in
the antitumor effect induced by As2O3 in human
glioma cells. These findings suggest that mitochondrial
mitoferrin-2 transporter may be an important potential
regulator in As2O3-induced glioma cell death and fur-
ther understanding mechanisms in both the therapeutic
activities and the toxicities of arsenic. Additionally, to-
gether with the multiple molecular targets affected by
arsenic, suggests the potential for additive or even syn-
ergistic effects when arsenic is administered with other
cytostatic or cytotoxic agents. Future studies are needed
to investigate whether mitoferrin-2 can take part in
As2O3 treatment in human glioma in vivo and in the
clinical setting.Abbreviations
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acid; PVDF: Polyvinylidene difluoride; MMP: Matrix metal proteinases;
PDT: Photodynamic therapy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XC carried out the molecular genetic studies, participated in the sequence
alignment and drafted the manuscript. XC participated in the design of the
study and performed the statistical analysis. HZ and YL conceived of the
study, and participated in its design and coordination and helped to draft
the manuscript. All authors read and approved the final manuscript.
Acknowledgement
This work was supported by grants from National Natural Science
Foundation of China (30973078, 81272788 to Shiguang Zhao; 81101616 to
Yunbo Zhen, and 81201974 to Lei Teng) and Foundation of the First
Affiliated Hospital of Harbin Medical University (2013B05 to Xiaofeng Chen).
Received: 10 January 2014 Accepted: 27 August 2014
References
1. Song X, Chen Z, Wu C, Zhao S: Abrogating HSP response augments cell
death induced by As2O3 in glioma cell lines. Can J Neurol Sci 2010,
37(4):504–511.
2. Haga N, Fujita N, Tsuruo T: Involvement of mitochondrial aggregation in
arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells.
Cancer Sci 2005, 96(11):825–833.
3. Yu M, Xue J, Li Y, Zhang W, Ma D, Liu L, Zhang Z: Resveratrol protects
against arsenic trioxide-induced nephrotoxicity by facilitating arsenic
metabolism and decreasing oxidative stress. Arch Toxicol 2013,
87(6):1025–1035.
4. Murphy MP: How mitochondria produce reactive oxygen species.
Biochem J 2009, 417:1–13.
5. Swanson CA: Iron intake and regulation: implications for iron deficiency
and iron overload. Alcohol 2003, 30(2):99–102.
6. Kohgo Y, Ohtake T, Ikuta K, Suzuki Y, Hosoki Y, Saito H, Kato J: Iron
accumulation in alcoholic liver diseases. Alcohol Clin Exp Res 2005,
29(11):189S–193S.
7. Petersen DR: Alcohol, iron-associated oxidative stress, and cancer.
Alcohol 2005, 35(3):243–249.
8. Imeryuz N, Tahan V, Sonsuz A, Eren F, Uraz S, Yuksel M, Akpulat S,
Ozcelik D, Haklar G, Celikel C, Avsar E, Tozun N: Iron preloading
aggravates nutritional steatohepatitis in rats by increasing apoptotic
cell death. J Hepatol 2007, 47(6):851–859.
9. Britton RS, Leicester KL, Bacon BR: Iron toxicity and chelation therapy.
Int J Hematol 2002, 76(3):219–228.
10. Eaton JW, Qian M: Molecular bases of cellular iron toxicity. Free Radic Biol
Med 2002, 32:833–840.
11. Shaw GC, Cope JJ, Li L, Corson K, Hersey C, Ackermann GE, Gwynn B,
Lambert AJ, Wingert RA, Traver D, Trede NS, Barut BA, Zhou Y, Minet E,
Donovan A, Brownlie A, Balzan R, Weiss MJ, Peters LL, Kaplan J, Zon LI,
Paw BH: Mitoferrin is essential for erythroid iron assimilation. Nature 2006,
440:96–100.
12. Uchiyama A, Kim JS, Kon K, Jaeschke H, Ikejima K, Watanabe S, Lemasters JJ:
Translocation of iron from lysosomes into mitochondria is a key event
during oxidative stress-induced hepatocellular injury. Hepatology 2008,
48:1644–1654.
13. Vineetha VP, Prathapan A, Soumya RS, Raghu KG: Arsenic trioxide toxicity
in H9c2 myoblasts - damage to cell organelles and possible amelioration
with Boerhavia diffusa. Cardiovasc Toxicol 2013, 13(2):123–137.
14. Richter C, Gogvadze V, Laffranchi R, Schlapbach R, Schweizer M, Suter M,
Walter P, Yaffee M: Oxidants in mitochondria: from physiology to
diseases. Biochim Biophys Acta 1995, 1271:67–74.
Wang et al. European Journal of Medical Research 2014, 19:49 Page 10 of 10
http://www.eurjmedres.com/content/19/1/4915. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ,
Achanta G, Arlinghaus RB, Liu J, Huang P: Selective killing of oncogenically
transformed cells through a ROS-mediated mechanism by beta-phenylethyl
isothiocyanate. Cancer Cell 2006, 10:241–252.
16. Krzywanski DM, Moellering DR, Fetterman JL, Dunham-Snary KJ, Sammy MJ,
Ballinger SW: The mitochondrial paradigm for cardiovascular disease
susceptibility and cellular function: a complementary concept to
Mendelian genetics. Lab Invest 2011, 91(8):1122–1135.
17. Satre M, Mattei S, Aubry L, Gaudet P, Pelosi L, Brandolin G, Klein G:
Mitochondrial carrier family: repertoire and peculiarities of the cellular
slime mould Dictyostelium discoideum. Biochimie 2007, 89:1058–1069.
18. Froschauer EM, Schweyen RJ, Wiesenberger G: The yeast mitochondrial
carrier proteins Mrs3p/Mrs4p mediate iron transport across the inner
mitochondrial membrane. Biochim Biophys Acta 2009, 1788:1044–1050.
19. Paradkar PN, Zumbrennen KB, Paw BH, Ward DM, Kaplan J: Regulation of
mitochondrial iron import through differential turnover of mitoferrin 1
and mitoferrin 2. Mol Cell Biol 2009, 29:1007–1016.
20. Hung HI, Schwartz JM, Maldonado EN, Lemasters JJ, Nieminen AL:
Mitoferrin-2-dependent mitochondrial iron uptake sensitizes human
head and neck squamous carcinoma cells to photodynamic therapy.
J Biol Chem 2013, 288(1):677–686.
21. Liu Y, Zhang X, Liang Y, Yu H, Chen X, Zheng T, Zheng B, Wang L, Zhao L,
Shi C, Zhao S: Targeting X box-binding protein-1 (XBP1) enhances
sensitivity of glioma cells to oxidative stress. Neuropathol Appl Neurobiol
2011, 37:395–405.
22. Yi J, Yang J, He R, Gao F, Sang H, Tang X, Ye RD: Emodin enhances arsenic
trioxide-induced apoptosis via generation of reactive oxygen species
and inhibition of survival signaling. Cancer Res 2004, 64:108–116.
23. Kim JH, Lew YS, Kolozsvary A, Ryu S, Brown SL: Arsenic trioxide enhances
radiation response of 9L glioma in the rat brain. Radiat Res 2003,
160(6):662–666.
24. Kanzawa T, Zhang L, Xiao L, Germano IM, Kondo Y, Kondo S: Arsenic
trioxide induces autophagic cell death in malignant glioma cells by
upregulation of mitochondrial cell death protein BNIP3. Oncogene 2005,
24(6):980–991.
25. Cohen KJ, Gibbs IC, Fisher PG, Hayashi RJ, Macy ME, Gore L: A phase I trial
of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of
childhood. Neuro Oncol 2013, 15(6):783–787.
26. Cai BZ, Meng FY, Zhu SL, Zhao J, Liu JQ, Liu CJ, Chen N, Ye ML, Li ZY, Ai J,
Lu YJ, Yang BF: Arsenic trioxide induces the apoptosis in bone marrow
mesenchymal stem cells by intracellular calcium signal and caspase-3
pathways. Toxicol Lett 2010, 193:173–178.
27. Yadav S, Shi Y, Wang F, Wang H: Arsenite induces apoptosis in human
mesenchymal stem cells by altering Bcl-2 family proteins and by
activating intrinsic pathway. Toxicol Appl Pharmacol 2010, 244:263–272.
28. Raghu KG, Cherian OL: Characterization of cytotoxicity induced by arsenic
trioxide (a potent anti-APL drug) in rat cardiac myocytes. J Trace Elem
Med Biol 2009, 23:61–68.
29. Li JX, Shen YQ, Cai BZ, Zhao J, Bai X, Lu YJ, Li XQ: Arsenic trioxide induces
the apoptosis in vascular smooth muscle cells via increasing intracellular
calcium and ROS formation. Mol Biol Rep 2010, 37:1569–1576.
30. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL,
Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD,
Chen SJ, Chen Z, Wang ZY: Use of arsenic trioxide (As2O3) in the
treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and
pharmacokinetics in relapsed patients. Blood 1997, 89:3354–3360.
31. Yen YP, Tsai KS, Chen YW, Huang CF, Yang RS, Liu SH: Arsenic induces
apoptosis in myoblasts through a reactive oxygen species-induced
endoplasmic reticulum stress and mitochondrial dysfunction pathway.
Arch Toxicol 2012, 86(6):923–933.
32. Kroemer G, de The H: Arsenic trioxide, a novel mitochondriotoxic
anticancer agent? J Natl Cancer Inst 1999, 91:743–745.
33. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP,
Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z, Chen GQ:
Apoptosis and growth inhibition in malignant lymphocytes after
treatment with arsenic trioxide at clinically achievable concentrations.
J Natl Cancer Inst 1999, 91:772–778.
34. Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T,
Nicot C: Arsenic trioxide induces apoptosis in human T-cell leukemia
virus type 1- and type 2-infected cells by a caspase-3-dependent
mechanism involving Bcl-2 cleavage. Blood 2001, 98:3762–3769.35. Kajiguchi T, Yamamoto K, Hossain K, Akhand AA, Nakashima I, Naoe T,
Saito H, Emi N: Sustained activation of c-jun-terminal kinase (JNK) is
closely related to arsenic trioxide-induced apoptosis in an acute myeloid
leukemia (M2)-derived cell line, NKM-1. Leukemia 2003, 17:2189–2195.
36. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A:
Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic
metastasis model of androgen-independent prostate cancer. Cancer Res
2001, 61:5432–5440.
37. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S: Mechanisms of
action of arsenic trioxide. Cancer Res 2002, 62:3893–3903.
38. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S: Arsenic trioxide
selectively induces acute promyelocytic leukemia cell apoptosis via a
hydrogen peroxide-dependent pathway. Blood 1999, 94:2102–2111.
39. Boonstra J, Post JA: Molecular events associated with reactive oxygen
species and cell cycle progression in mammalian cells. Gene 2004,
4(337):1–13.
40. Kanda Y, Hinata T, Kang SW, Watanabe Y: Reactive oxygen species
mediate adipocyte differentiation in mesenchymal stem cells. Life Sci
2011, 89(7–8):250–258.
41. Orrenius S: Reactive oxygen species in mitochondria-mediated cell death.
Drug Metab Rev 2007, 39(2–3):443–455.
42. Antonsson B, Montessuit S, Sanchez B, Martinou JC: Bax is present as a
high molecular weight oligomer/complex in the mitochondrial
membrane of apoptotic cells. J Biol Chem 2001, 276(15):11615–11623.
43. Huang ML, Becker EM, Whitnall M, Suryo Rahmanto Y, Ponka P, Richardson
DR: Elucidation of the mechanism of mitochondrial iron loading in
Friedreich’s ataxia by analysis of a mouse mutant. Proc Natl Acad Sci
U S A 2009, 106:16381–16386.
44. Yaguang R, Su Y, Tan G, Ye W, Liu D, Qian X, Ding Z, Zhong Y, Zhang J,
Jiang D, Zhao Y, Lu J: Reduction of mitoferrin results in abnormal
development and extended lifespan in Caenorhabditis elegans. PLoS One
2012, 7(1):e29666.
doi:10.1186/s40001-014-0049-5
Cite this article as: Wang et al.: The roles of mitoferrin-2 in the process
of arsenic trioxide-induced cell damage in human gliomas. European
Journal of Medical Research 2014 19:49.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
